Abstract
Class III β-tubulin (TUBB3) is a prominent mechanism of drug resistance expressed in a variety of solid tumors and particularly in lung and ovarian cancer. In the classical view, TUBB3 expression and drug resistance have been linked, and together they have been associated with a perturbation in microtubule dynamics. In keeping with this observation, TUBB3 was associated with drug resistance only when chemotherapy included a taxane in its chemical composition. In this review, we demonstrate that the classical supposition about TUBB3 is not correct, and that instead TUBB3 expression is linked to drug resistance as a complex survival mechanism activated by microenvironmental conditions such as poor nutrient supply and hypoxia.
Keywords: Tubulin, biomarkers, drug-resistance, poor outcome, pharmacogenomics, toxicity, biomediators, myeloid leukemia, tumors, imatinib, dasatinib, nilotinib, oncogene, carcinoma, angiogenesis
Current Molecular Medicine
Title: Class III β -Tubulin (TUBB3): More than a Biomarker in Solid Tumors?
Volume: 11 Issue: 9
Author(s): M. Mariani, S. Shahabi, S. Sieber, G. Scambia and C. Ferlini
Affiliation:
Keywords: Tubulin, biomarkers, drug-resistance, poor outcome, pharmacogenomics, toxicity, biomediators, myeloid leukemia, tumors, imatinib, dasatinib, nilotinib, oncogene, carcinoma, angiogenesis
Abstract: Class III β-tubulin (TUBB3) is a prominent mechanism of drug resistance expressed in a variety of solid tumors and particularly in lung and ovarian cancer. In the classical view, TUBB3 expression and drug resistance have been linked, and together they have been associated with a perturbation in microtubule dynamics. In keeping with this observation, TUBB3 was associated with drug resistance only when chemotherapy included a taxane in its chemical composition. In this review, we demonstrate that the classical supposition about TUBB3 is not correct, and that instead TUBB3 expression is linked to drug resistance as a complex survival mechanism activated by microenvironmental conditions such as poor nutrient supply and hypoxia.
Export Options
About this article
Cite this article as:
Mariani M., Shahabi S., Sieber S., Scambia G. and Ferlini C., Class III β -Tubulin (TUBB3): More than a Biomarker in Solid Tumors?, Current Molecular Medicine 2011; 11 (9) . https://dx.doi.org/10.2174/156652411798062368
DOI https://dx.doi.org/10.2174/156652411798062368 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Autoantibody Profiles as Biomarkers for Response to Therapy and Early Detection of Cancer
Current Cancer Therapy Reviews Designing Prodrugs Based on Special Residues of Human Serum Albumin
Current Topics in Medicinal Chemistry Neuroprotective Effects of Quercetin: From Chemistry to Medicine
CNS & Neurological Disorders - Drug Targets Ellagic Acid Enhances the Efficacy of PI3K Inhibitor GDC-0941 in Breast Cancer Cells
Current Molecular Medicine PKC Delta and Epsilon in Drug Targeting and Therapeutics
Recent Patents on DNA & Gene Sequences The Proteasome in Health and Disease
Current Pharmaceutical Design An Update of In Silico Tools for the Prediction of Pathogenesis in Missense Variants
Current Bioinformatics Cytoskeletal Alterations that Confer Resistance to Anti-tubulin Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry The Potential Anti-Tumorigenic and Anti-Metastatic Side of the Proprotein Convertases Inhibitors
Recent Patents on Anti-Cancer Drug Discovery Polymer – Nanoparticle Assemblies for Array Based Sensing
Current Organic Chemistry Regulation of Cell Growth by Estrogen Signaling and Potential Targets in Thyroid Cancer
Current Cancer Drug Targets The ErbB Receptors and their Ligands in Cancer: An Overview
Current Drug Targets Regulation of Expression and Function of IDO in Human Dendritic Cells
Current Medicinal Chemistry An Update on the Other Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Medicinal Chemistry Reviews - Online (Discontinued) Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is Promising
Current Drug Metabolism Breast Cancer: Current Developments in Molecular Approaches to Diagnosis and Treatment
Recent Patents on Anti-Cancer Drug Discovery The Power of Biomarkers in Transforming Patients Care in Gynecologic Oncology
Current Drug Targets Long Non-coding RNA HOTAIR Promotes Parkinson's Disease Induced by MPTP Through up-regulating the Expression of LRRK2
Current Neurovascular Research Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design Antioxidant Effect of Mangiferin and its Potential to be a Cancer Chemoprevention Agent
Letters in Drug Design & Discovery